Treatment Protocol

Initiate SGLT-2 inhibitor or GLP-1 receptor agonist at discharge if indicated.

Stop canagliflozin, dapagliflozin, empagliflozin ≥3 days and ertugliflozin ≥4 days prior to surgery.

Consider initiating low-dose colchicine (0.5 mg or 0.6 mg daily) for secondary prevention.

Do not use in patients with blood dyscrasias, renal failure (CrCl <15 mL/min), severe hepatic impairment, or concomitant P-glycoprotein/strong CYP3A4 inhibitors.

Administer influenza vaccine before discharge or at first follow-up.

Follow CDC immunization schedules for other vaccines (e.g., COVID-19, pneumococcal) as indicated.